Watson C - Search Results

1

Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.

Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, Gandra SR. Hone D, et al. Among authors: watson c. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1564-72. doi: 10.1002/acr.22022. Arthritis Care Res (Hoboken). 2013. PMID: 23554320 Free article.

2

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Bonafede MM, et al. Among authors: watson c. Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9. Adv Ther. 2012. PMID: 22411424

3

Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.

Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR. Fisher MD, et al. Among authors: watson c. Curr Med Res Opin. 2013 May;29(5):561-8. doi: 10.1185/03007995.2013.786693. Epub 2013 Apr 3. Curr Med Res Opin. 2013. PMID: 23489410

4

Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.

Chastek B, Fox KM, Watson C, Gandra SR. Chastek B, et al. Among authors: watson c. Adv Ther. 2012 Aug;29(8):691-7. doi: 10.1007/s12325-012-0039-3. Epub 2012 Aug 16. Adv Ther. 2012. PMID: 22903239

5

Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.

Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR. Bonafede MM, et al. Among authors: watson c. Clin Ther. 2012 Feb;34(2):457-67. doi: 10.1016/j.clinthera.2011.12.016. Epub 2012 Jan 28. Clin Ther. 2012. PMID: 22284901

6

Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population.

Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Chastek B, et al. Among authors: watson c. J Dermatolog Treat. 2013 Feb;24(1):25-33. doi: 10.3109/09546634.2012.661038. Epub 2012 Jun 5. J Dermatolog Treat. 2013. PMID: 22668321 Free article.

7

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.

Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Bonafede M, et al. Among authors: watson c. J Dermatolog Treat. 2013 Oct;24(5):369-73. doi: 10.3109/09546634.2012.755255. Epub 2013 May 21. J Dermatolog Treat. 2013. PMID: 23441722 Free PMC article.

8

Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.

Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Yeaw J, et al. Among authors: watson c. Adv Ther. 2014 Apr;31(4):410-25. doi: 10.1007/s12325-014-0110-3. Epub 2014 Mar 7. Adv Ther. 2014. PMID: 24604700

9

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Schabert VF, et al. Among authors: watson c. J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8. J Med Econ. 2012. PMID: 22115327 Free article.

10

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Bonafede M, et al. Among authors: watson c. Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8. Adv Ther. 2012. PMID: 22886712

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,421 results

Search Page

Filters